189 related articles for article (PubMed ID: 8648761)
21. Construction and characterization of chimeric tick-borne encephalitis/dengue type 4 viruses.
Pletnev AG; Bray M; Huggins J; Lai CJ
Proc Natl Acad Sci U S A; 1992 Nov; 89(21):10532-6. PubMed ID: 1438242
[TBL] [Abstract][Full Text] [Related]
22. Induction of tetravalent protective immunity against four dengue serotypes by the tandem domain III of the envelope protein.
Chen S; Yu M; Jiang T; Deng Y; Qin C; Qin E
DNA Cell Biol; 2007 Jun; 26(6):361-7. PubMed ID: 17570760
[TBL] [Abstract][Full Text] [Related]
23. Development of a live attenuated dengue virus vaccine using reverse genetics.
Blaney JE; Durbin AP; Murphy BR; Whitehead SS
Viral Immunol; 2006; 19(1):10-32. PubMed ID: 16553547
[TBL] [Abstract][Full Text] [Related]
24. Comparison of live and inactivated tick-borne encephalitis virus vaccines for safety, immunogenicity and efficacy in rhesus monkeys.
Rumyantsev AA; Chanock RM; Murphy BR; Pletnev AG
Vaccine; 2006 Jan; 24(2):133-43. PubMed ID: 16115704
[TBL] [Abstract][Full Text] [Related]
25. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates.
Monath TP; Soike K; Levenbook I; Zhang ZX; Arroyo J; Delagrave S; Myers G; Barrett AD; Shope RE; Ratterree M; Chambers TJ; Guirakhoo F
Vaccine; 1999 Apr; 17(15-16):1869-82. PubMed ID: 10217584
[TBL] [Abstract][Full Text] [Related]
26. Use of a Recombinant Gamma-2 Herpesvirus Vaccine Vector against Dengue Virus in Rhesus Monkeys.
Bischof GF; Magnani DM; Ricciardi M; Shin YC; Domingues A; Bailey VK; Gonzalez-Nieto L; Rakasz EG; Watkins DI; Desrosiers RC
J Virol; 2017 Aug; 91(16):. PubMed ID: 28592531
[TBL] [Abstract][Full Text] [Related]
27. Mutational analysis of a neutralization epitope on the dengue type 2 virus (DEN2) envelope protein: monoclonal antibody resistant DEN2/DEN4 chimeras exhibit reduced mouse neurovirulence.
Hiramatsu K; Tadano M; Men R; Lai CJ
Virology; 1996 Oct; 224(2):437-45. PubMed ID: 8874504
[TBL] [Abstract][Full Text] [Related]
28. Induction of protective immunity against Dengue virus type 2: comparison of candidate live attenuated and recombinant vaccines.
Velzing J; Groen J; Drouet MT; van Amerongen G; Copra C; Osterhaus AD; Deubel V
Vaccine; 1999 Mar; 17(11-12):1312-20. PubMed ID: 10195766
[TBL] [Abstract][Full Text] [Related]
29. A dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies and provides protection from viral challenge in Aotus monkeys.
Kochel TJ; Raviprakash K; Hayes CG; Watts DM; Russell KL; Gozalo AS; Phillips IA; Ewing DF; Murphy GS; Porter KR
Vaccine; 2000 Jul; 18(27):3166-73. PubMed ID: 10856796
[TBL] [Abstract][Full Text] [Related]
30. Protection of Rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination.
Sun W; Nisalak A; Gettayacamin M; Eckels KH; Putnak JR; Vaughn DW; Innis BL; Thomas SJ; Endy TP
J Infect Dis; 2006 Jun; 193(12):1658-65. PubMed ID: 16703509
[TBL] [Abstract][Full Text] [Related]
31. Introduction of mutations into the non-structural genes or 3' untranslated region of an attenuated dengue virus type 4 vaccine candidate further decreases replication in rhesus monkeys while retaining protective immunity.
Hanley KA; Manlucu LR; Manipon GG; Hanson CT; Whitehead SS; Murphy BR; Blaney JE
Vaccine; 2004 Sep; 22(25-26):3440-8. PubMed ID: 15308370
[TBL] [Abstract][Full Text] [Related]
32. Induction of bivalent immune responses by expression of dengue virus type 1 and type 2 antigens from a single complex adenoviral vector.
Raja NU; Holman DH; Wang D; Raviprakash K; Juompan LY; Deitz SB; Luo M; Zhang J; Porter KR; Dong JY
Am J Trop Med Hyg; 2007 Apr; 76(4):743-51. PubMed ID: 17426182
[TBL] [Abstract][Full Text] [Related]
33. Derivation and characterization of a dengue type 1 host range-restricted mutant virus that is attenuated and highly immunogenic in monkeys.
Markoff L; Pang X; Houng Hs HS; Falgout B; Olsen R; Jones E; Polo S
J Virol; 2002 Apr; 76(7):3318-28. PubMed ID: 11884557
[TBL] [Abstract][Full Text] [Related]
34. West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy.
Pletnev AG; Putnak R; Speicher J; Wagar EJ; Vaughn DW
Proc Natl Acad Sci U S A; 2002 Mar; 99(5):3036-41. PubMed ID: 11880643
[TBL] [Abstract][Full Text] [Related]
35. Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates.
Guirakhoo F; Pugachev K; Zhang Z; Myers G; Levenbook I; Draper K; Lang J; Ocran S; Mitchell F; Parsons M; Brown N; Brandler S; Fournier C; Barrere B; Rizvi F; Travassos A; Nichols R; Trent D; Monath T
J Virol; 2004 May; 78(9):4761-75. PubMed ID: 15078958
[TBL] [Abstract][Full Text] [Related]
36. A chimeric dengue virus vaccine using Japanese encephalitis virus vaccine strain SA14-14-2 as backbone is immunogenic and protective against either parental virus in mice and nonhuman primates.
Li XF; Deng YQ; Yang HQ; Zhao H; Jiang T; Yu XD; Li SH; Ye Q; Zhu SY; Wang HJ; Zhang Y; Ma J; Yu YX; Liu ZY; Li YH; Qin ED; Shi PY; Qin CF
J Virol; 2013 Dec; 87(24):13694-705. PubMed ID: 24109223
[TBL] [Abstract][Full Text] [Related]
37. Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys.
Clements DE; Coller BA; Lieberman MM; Ogata S; Wang G; Harada KE; Putnak JR; Ivy JM; McDonell M; Bignami GS; Peters ID; Leung J; Weeks-Levy C; Nakano ET; Humphreys T
Vaccine; 2010 Mar; 28(15):2705-15. PubMed ID: 20097152
[TBL] [Abstract][Full Text] [Related]
38. A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys.
Guirakhoo F; Zhang Z; Myers G; Johnson BW; Pugachev K; Nichols R; Brown N; Levenbook I; Draper K; Cyrek S; Lang J; Fournier C; Barrere B; Delagrave S; Monath TP
J Virol; 2004 Sep; 78(18):9998-10008. PubMed ID: 15331733
[TBL] [Abstract][Full Text] [Related]
39. Immunogenicity and efficacy of flagellin-envelope fusion dengue vaccines in mice and monkeys.
Liu G; Song L; Beasley DW; Putnak R; Parent J; Misczak J; Li H; Reiserova L; Liu X; Tian H; Liu W; Labonte D; Duan L; Kim Y; Travalent L; Wigington D; Weaver B; Tussey L
Clin Vaccine Immunol; 2015 May; 22(5):516-25. PubMed ID: 25761459
[TBL] [Abstract][Full Text] [Related]
40. Tetravalent neutralizing antibody response against four dengue serotypes by a single chimeric dengue envelope antigen.
Apt D; Raviprakash K; Brinkman A; Semyonov A; Yang S; Skinner C; Diehl L; Lyons R; Porter K; Punnonen J
Vaccine; 2006 Jan; 24(3):335-44. PubMed ID: 16125280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
